Did everyone miss this?

The in-depth analysis of the entire Phase IIb study of NTCELL data by statisticians and other experts indicates to progress NTCELL towards a marketable product LCT would have to undertake a larger Phase III study which would require further resources and clinical study design. Strategies to achieve the above mission include: • With expert input explore the feasibility of a confirmative larger Phase III study in NTCELL. • Continue with our initial proof-of-principle projects that led to the designed and establishment of research partnerships with the globally recognised Chemical Sciences department at the University of Auckland to proceed with therapeutic targets that include migraine and anti-obesity. Prospects for future years include execution of the above strategies to create value for shareholders by maximising the number and quality of target opportunities for ACHIEVING REVENUES IN THE NEAR FUTURE..

... When news starts to trickle through about migraine cures and anti obesity in-plants the super low SP that we are stuck with at the moment should at least double.....and LCT are aiming to achieve revenues for the share holders in the NEAR FUTURE